Inventor · disambiguated record
Gundram Jung
Also filed as: JUNG GUNDRAM
8 granted patents·10 pending applications·99 citations·filing 2002–2025
84Inventor score
Files withDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS6JUNG GUNDRAM3SYNIMMUNE GMBH2UNIV TUEBINGEN MEDIZINISCHE FAKULTAET2DEUTSCHES KREBSFORSCH1
Top patents by PatentIndex Score
18 records- 0190US9718893B2Bispecific antibody moleculeSYNIMMUNE GMBH·Filed 2012·Granted Aug 1, 2017·57 cites·13 claims
- 0287US7538196B2Bispecific antibody moleculeJUNG GUNDRAM·Filed 2002·Granted May 26, 2009·26 cites·6 claims
- 0378US11612646B2PSMA binding antibody and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Granted Mar 28, 2023·2 cites·8 claims
- 0476US8058399B2Multispecific reagent for selectively stimulating cell surface receptorsJUNG GUNDRAM·Filed 2003·Granted Nov 15, 2011·13 cites·2 claims
- 0574US2025346669A1Psma binding antibody and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2025·Application pending·0 cites
- 0673US12398208B2PSMA binding antibody and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2022·Granted Aug 26, 2025·0 cites·5 claims
- 0767US2025197510A1Anti-FLT3 Antigen Binding ProteinsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2024·Application pending·0 cites
- 0865US9624310B2Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cellsJUNG GUNDRAM·Filed 2012·Granted Apr 18, 2017·1 cites·30 claims
- 0956US2022153816A1Antiviral immunotherapy by membrane receptor ligationUNIV TUEBINGEN MEDIZINISCHE FAKULTAET·Filed 2021·Application pending·0 cites
- 1054US12195543B2Anti-FLT3 antigen binding proteinsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS·Filed 2019·Granted Jan 14, 2025·0 cites·11 claims
- 1152US11208469B2Antiviral immunotherapy by membrane receptor ligationUNIV TUEBINGEN MEDIZINISCHE FAKULTAET·Filed 2018·Granted Dec 28, 2021·0 cites·3 claims
- 1250US2023406961A1Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodiesDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2021·Application pending·0 cites
- 1346US2023007977A1Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2020·Application pending·0 cites
- 1445US2010068145A1Bispecific fusion protein having therapeutic and diagnostic potentialUNIV EBERHARD KARLS·Filed 2009·Application pending·0 cites
- 1544US2002115134A1Simplified production of bispecific antibody fragmentsFiled 2002·Application pending·0 cites
- 1640US2018057608A1Bispecific antibody moleculeSYNIMMUNE GMBH·Filed 2017·Application pending·0 cites
- 1734US2017362325A1Use of blocking-reagents for reducing unspecific t cell-activationDEUTSCHES KREBSFORSCH·Filed 2015·Application pending·0 cites
- 1831US2018208657A1Recombinant antibody molecule and its use for target cell restricted t cell activationUNIV WUERZBURG J MAXIMILIANS·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →